SCHEMBL23948144

SCHEMBL23948144

CSc1ncc(C(=O)O)c(NC2CCOCC2F)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 11/20 0.38
PDE4B Q07343 3/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SYK P43405 4/20 0.37
MAPK3 P27361 3/20 0.36
MAPK1 P28482 3/20 0.36
KCNH2 Q12809 2/20 0.36
AURKB Q96GD4 2/20 0.36
JAK2 O60674 1/20 0.36
LCK P06239 1/20 0.36
LYN P07948 1/20 0.36
JAK1 P23458 1/20 0.36
ZAP70 P43403 1/20 0.36
JAK3 P52333 1/20 0.36
TYRO3 Q06418 1/20 0.36
TNF P01375 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23948142 0.86 ALDH1A1 (0.52) PDE4BMEN1KMT2ASYKMAPK1
SCHEMBL29502030 0.86 ALDH1A1 (0.52) PDE4BMEN1KMT2ASYKMAPK1
SCHEMBL5748532 0.84 PDE4B (0.44) PDE4BMEN1KMT2ASYKMAPK1
SCHEMBL23948514 0.82 PDE4B (0.48) PDE4BMEN1KMT2ASYKMAPK1
SCHEMBL15249748 0.77 SYK (0.51) PDE4BMEN1KMT2ASYK
SCHEMBL14657268 0.76 MAPK8 (0.45) MEN1KMT2ASYKJAK2JAK1
SCHEMBL26161013 0.75 SYK (0.49) MEN1KMT2ASYK
SCHEMBL1226594 0.75 MEN1 (0.49) MEN1KMT2ASYK
SCHEMBL22585848 0.75 NPC1 (0.40) PDE4BMEN1KMT2ASYKMAPK1
SCHEMBL20955933 0.75 NR3C1 (0.36) PDE4BMEN1KMT2ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 IRAK4 1455/4885PDE4B 1193/4885MEN1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.